The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis
暂无分享,去创建一个
E. Antman | M. Sabatine | E. Braunwald | S. Murphy | C. McCabe | P. Steg | V. Fridrich | P. Steg | M. O’Donoghue | S. Wiviott | A. Finkelstein | W. Penny
[1] E. Antman,et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.
[2] M. Nauck,et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes , 2002, The Lancet.
[3] B. Engelmann,et al. Platelet ADP receptors contribute to the initiation of intravascular coagulation. , 2004, Blood.
[4] A. Kastrati,et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.
[5] R. Storey,et al. Effects of P2Y 1 and P2Y 12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood , 2001, Platelets.
[6] E. Antman,et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. , 2008, Journal of the American College of Cardiology.
[7] S. Steinhubl,et al. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. , 2008, American heart journal.
[8] A. Siegbahn,et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. , 2006, European heart journal.
[9] A. Weyrich,et al. Platelets, endothelial cells, inflammatory chemokines, and restenosis: complex signaling in the vascular play book. , 2002, Circulation.
[10] J. Ornato,et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.
[11] E. Antman,et al. Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial , 2007, Circulation.
[12] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[13] A. Siegbahn,et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. , 2007, European heart journal.
[14] K. Winters,et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. , 2007, American heart journal.
[15] K. Winters,et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans , 2006, Platelets.
[16] Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. , 1998, The New England journal of medicine.
[17] G. Montalescot,et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. , 2006, Journal of the American College of Cardiology.
[18] M. O’Donoghue,et al. Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All? , 2006, Circulation.
[19] Carl J Pepine,et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.
[20] P. Teirstein,et al. Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study , 2001, Circulation.
[21] Ralph D'Agostino,et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.
[22] E. Antman,et al. Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.
[23] William Wijns,et al. [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
[24] Stgrp Capture,et al. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.
[25] R. Califf,et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. , 2006, Archives of internal medicine.
[26] P. Conley,et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. , 2003, The Journal of clinical investigation.